Quintet Private Bank Europe S.A. Lowers Holdings in Bristol Myers Squibb Company $BMY

Quintet Private Bank Europe S.A. reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 90.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,790 shares of the biopharmaceutical company’s stock after selling 33,970 shares during the period. Quintet Private Bank Europe S.A.’s holdings in Bristol Myers Squibb were worth $236,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Vann Equity Management LLC bought a new position in Bristol Myers Squibb in the 3rd quarter valued at $296,000. Steph & Co. increased its holdings in Bristol Myers Squibb by 5.5% in the third quarter. Steph & Co. now owns 8,491 shares of the biopharmaceutical company’s stock valued at $530,000 after purchasing an additional 446 shares during the last quarter. Elevation Wealth Partners LLC raised its position in shares of Bristol Myers Squibb by 13.1% in the 3rd quarter. Elevation Wealth Partners LLC now owns 1,603 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 186 shares during the period. Cooper Financial Group boosted its position in shares of Bristol Myers Squibb by 3.2% during the third quarter. Cooper Financial Group now owns 12,784 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 397 shares in the last quarter. Finally, Canandaigua National Trust Co of Florida acquired a new position in Bristol Myers Squibb in the third quarter valued at about $394,000. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 Zenbexustm data: Bristol Myers Squibb reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed and refractory multiple myeloma. The result strengthens BMY’s pipeline and could support a future growth driver in a competitive market. Bristol Myers Squibb Announces Zenbexus Phase 3 Results
• Positive Sentiment: Growth from newer medicines: Reblozyl’s strong sales and additional indications may help offset declines from older products. BMY also secured a Camzyos label expansion, potentially broadening the drug’s commercial opportunity. Reblozyl Growth Outlook
• Neutral Sentiment: Sotyktu adoption is developing unevenly: Rheumatologists are increasingly using the oral TYK2 inhibitor for psoriatic arthritis and recognize its differentiation, but limited experience, access hurdles and questions about joint efficacy are restraining its launch momentum. Sotyktu Psoriatic Arthritis Adoption
• Negative Sentiment: Analyst price-target reduction: Cantor Fitzgerald lowered its BMY target from $59 to $53 and maintained a neutral rating, signaling limited near-term upside in its view.
• Negative Sentiment: Patent-cliff concerns remain: Analysts continue to highlight the risk that patent expirations and declining legacy-drug sales could pressure revenue, increasing the importance of successful launches and pipeline development. Bristol Myers Squibb Patent Cliff Analysis

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Price Performance

NYSE:BMY traded down $0.31 on Thursday, hitting $59.39. The company had a trading volume of 3,667,516 shares, compared to its average volume of 11,966,175. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The firm has a 50 day moving average of $64.38 and a two-hundred day moving average of $60.27. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $121.31 billion, a price-to-earnings ratio of 13.08, a PEG ratio of 0.28 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Citigroup restated a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $63.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, September 23rd. Finally, Truist Financial reaffirmed a “buy” rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.72.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.